Drug intelligence / Profile preview

autologous bone marrow stem cells + tricalcium phosphate + demineralized bone matrix

Development stage
Unknown
Lead developer
Medtronic
Modality
Cell Therapies
Administration
Implant
01

Overview

This therapeutic combination is a composite bone graft substitute that utilizes the 'diamond concept' of bone healing by integrating osteogenic, osteoconductive, and osteoinductive elements. It consists of **autologous bone marrow stem cells (BMSCs)**, which provide the cellular machinery (osteogenesis) for new bone formation; **tricalcium phosphate (TCP)**, a synthetic ceramic that serves as a porous, resorbable scaffold (osteoconduction) for cell attachment and mineral deposition; and **demineralized bone matrix (DBM)**, an allograft-derived matrix that provides essential growth factors, primarily bone morphogenetic proteins (BMPs), to trigger the differentiation of progenitor cells into bone-forming osteoblasts (osteoinduction). This combination is frequently employed in complex orthopedic procedures, including the treatment of non-unions, large bone defects, and spinal fusions, where a single-component graft may be insufficient.

Other names
BMSC + TCP + DBMcomposite bone graftbone marrow aspirate concentrate + tricalcium phosphate + demineralized bone matrix

Beyond the preview

Go deeper on autologous bone marrow stem cells + tricalcium phosphate + demineralized bone matrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous bone marrow stem cells + tricalcium phosphate + demineralized bone matrix.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call